Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YS247 in Recurrent or Progressive Glioblastoma
NCT07678138Not yet recruiting
- Sponsor
- Tianjin Huanhu Hospital
- Start
- Jun 2026
- Primary completion
- Nov 2027
01
Overview
Open-label, single-arm trial of YS247 in glioblastoma (GBM), sponsored by Tianjin Huanhu Hospital. Primary endpoints: Safety and Treatment Tolerability at 16 weeks and Maximum Tolerated Dose and Recommended Expanded Dose at 16 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
YS247
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07678138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678138.